TDXd now @US_FDA โ in neoadjuvant and adjuvant high risk residual HER2+ breast cancer based off DESTINYBreast05 and DESTINYBreast11:
- โฌ๏ธ pCR & iDFS w/ TDXd
- Timings of RT did NOT impact the incidence or severity of ILD
- New Soc for high risk disease!
#bcsm#OncTwitter
What happened behind the meeting in Seattle was powerful. Global speakers, hands-on learning, advanced clinical practice, and meaningful collaboration all moved breast care forward. Preorder the online experience and revisit the moments.
https://t.co/PCE87JZI8C